See more : MetroGlobal Limited (METROGLOBL.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Immunome, Inc. (IMNM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Immunome, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Hippo Holdings Inc. WT (HIPO-WT) Income Statement Analysis – Financial Results
- Wah Hong Industrial Corp. (8240.TWO) Income Statement Analysis – Financial Results
- RattanIndia Enterprises Limited (RTNINDIA.NS) Income Statement Analysis – Financial Results
- Nippon BS Broadcasting Corporation (9414.T) Income Statement Analysis – Financial Results
- EXCO Resources, Inc. (EXCE) Income Statement Analysis – Financial Results
Immunome, Inc. (IMNM)
About Immunome, Inc.
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 14.02M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 22.93M | 631.00K | 755.00K | 755.00K | 615.00K | 521.00K |
| Gross Profit | -8.91M | -631.00K | -755.00K | -755.00K | -615.00K | -521.00K |
| Gross Profit Ratio | -63.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 80.80M | 23.27M | 14.11M | 7.49M | 8.82M | 6.88M |
| General & Administrative | 19.66M | 13.63M | 11.09M | 4.78M | 1.53M | 866.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 19.66M | 13.63M | 11.09M | 4.78M | 1.53M | 866.00K |
| Other Expenses | 0.00 | 0.00 | 503.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 122.82M | 36.90M | 25.20M | 12.26M | 10.35M | 7.74M |
| Cost & Expenses | 123.55M | 36.90M | 25.20M | 12.26M | 10.35M | 7.74M |
| Interest Income | 2.72M | 5.00K | 10.00K | 1.00K | 10.00K | 39.00K |
| Interest Expense | 0.00 | 5.00K | 10.00K | 38.00K | 106.00K | 141.00K |
| Depreciation & Amortization | 728.00K | 631.00K | 755.00K | 755.00K | 615.00K | 521.00K |
| EBITDA | -28.27M | -36.27M | -23.95M | -17.04M | -9.72M | -7.18M |
| EBITDA Ratio | -201.68% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -109.53M | -36.90M | -25.20M | -12.26M | -10.35M | -7.74M |
| Operating Income Ratio | -781.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.72M | 5.00K | 493.00K | -5.58M | -96.00K | -102.00K |
| Income Before Tax | -106.81M | -36.90M | -24.71M | -17.84M | -10.44M | -7.85M |
| Income Before Tax Ratio | -761.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 617.00K | -242.00K | -717.00K | 106.00K | 39.00K |
| Net Income | -106.81M | -37.51M | -24.47M | -17.12M | -10.55M | -7.85M |
| Net Income Ratio | -761.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -5.38 | -3.09 | -2.12 | -1.69 | -1.84 | -7.18 |
| EPS Diluted | -5.38 | -3.09 | -2.12 | -1.69 | -1.84 | -7.18 |
| Weighted Avg Shares Out | 19.84M | 12.13M | 11.54M | 10.11M | 5.74M | 1.09M |
| Weighted Avg Shares Out (Dil) | 19.84M | 12.13M | 11.54M | 10.11M | 5.74M | 1.09M |
Immunome: AL102 And Other Established Protein Targets Could Drive Value
Top-line data from Part B of phase 3 RINGSIDE study, using AL102 for the treatment of patients with desmoid tumors, expected 2nd half of 2025. The global desmoid tumor market is projected to grow to $5.49 billion by 2032. IM-1021...
Immunome Announces Completion of Purchase of Assets from Atreca
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the completion of its purchase of antibodies and related assets from Atreca, Inc. Under the terms of the agreement, Immunome...
Immunome Announces Promotion of Max Rosett to Chief Financial Officer
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the promotion of Max Rosett to Chief Financial Officer, effective May 9. Mr. Rosett most recently held the role of...
Immunome, Inc. (IMNM) Reports Q1 Loss, Misses Revenue Estimates
Immunome, Inc. (IMNM) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.80. This compares to loss of $0.35 per share a year ago.
Immunome Reports First Quarter 2024 Financial Results and Provides Business Update
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the first quarter ended March 31, 2024, and provided a business update. “Immunome continues to build momentum....
Immunome to Present at 2024 Bank of America Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and Chief Executive Officer, will present at the 2024 Bank of America Healthcare Conference on...
Immunome Appoints Kinney Horn as Chief Business Officer
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Kinney Horn as Chief Business Officer. Mr. Horn brings to Immunome extensive experience across life sciences corporate...
Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for
Immunome (IMNM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Immunome Appoints Sandra M. Swain to Board of Directors
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Sandra M. Swain, M.D., to its Board of Directors. Dr. Swain has over 30 years of oncology...
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will present preclinical data for IM-3050, the company's lead lutetium-177 radioligand therapy (RLT) targeting fibroblast activation protein (FAP)....
Source: https://incomestatements.info
Category: Stock Reports